farampator Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Farampator is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity.   Wikipedia

Chemistry

  • SMILES: O=C(N1CCCCC1)c2ccc3nonc3c2
  • InChIKey: XFVRBYKKGGDPAJ-UHFFFAOYSA-N
  • Mol. Mass: 231.25
  • ALogP: 1.85
  • ChEMBL Molecule:
    farampator  
More Chemistry

Pharmacology

Alternative names

1-(benzofurazan-5-ylcarbonyl)piperidine | 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole | cx-691 | farampator | org 24448 | org-24448 | sch 900460 | sch-900460

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Depression (Phase 2)

Depressive Disorder, Major (Phase 2)

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue